Moderna's vaccine sales have dipped, prompting the company to focus on cost cuts and its pipeline. However, the company has seen a revenue bump from international COVID vaccine sales and is making progress with other vaccine trials, including an mRNA bird flu vaccine. The company's financial situation and vaccine development pipeline are subject to various challenges and developments, including patent disputes and regulatory approvals.